[go: up one dir, main page]

AP2014008139A0 - Acrylamide compounds as histamine H3 receptor ligands - Google Patents

Acrylamide compounds as histamine H3 receptor ligands

Info

Publication number
AP2014008139A0
AP2014008139A0 AP2014008139A AP2014008139A AP2014008139A0 AP 2014008139 A0 AP2014008139 A0 AP 2014008139A0 AP 2014008139 A AP2014008139 A AP 2014008139A AP 2014008139 A AP2014008139 A AP 2014008139A AP 2014008139 A0 AP2014008139 A0 AP 2014008139A0
Authority
AP
ARIPO
Prior art keywords
histamine
receptor ligands
acrylamide compounds
acrylamide
compounds
Prior art date
Application number
AP2014008139A
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Adi Reddy Dwarampudi
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of AP2014008139A0 publication Critical patent/AP2014008139A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AP2014008139A 2012-08-23 2012-12-05 Acrylamide compounds as histamine H3 receptor ligands AP2014008139A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3464CH2012 2012-08-23
PCT/IN2012/000796 WO2014030170A1 (en) 2012-08-23 2012-12-05 Acrylamide compounds as histamine h3 receptor ligands

Publications (1)

Publication Number Publication Date
AP2014008139A0 true AP2014008139A0 (en) 2014-12-31

Family

ID=54187093

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014008139A AP2014008139A0 (en) 2012-08-23 2012-12-05 Acrylamide compounds as histamine H3 receptor ligands

Country Status (26)

Country Link
US (1) US9328092B2 (es)
EP (1) EP2888243B1 (es)
JP (1) JP5981654B2 (es)
KR (1) KR101707343B1 (es)
CN (1) CN104540812B (es)
AP (1) AP2014008139A0 (es)
AU (1) AU2012388383C1 (es)
BR (1) BR112015001524B1 (es)
CA (1) CA2878217C (es)
CY (1) CY1118035T1 (es)
DK (1) DK2888243T3 (es)
EA (1) EA025136B1 (es)
ES (1) ES2592819T3 (es)
HR (1) HRP20161167T1 (es)
HU (1) HUE030901T2 (es)
IL (1) IL236437A (es)
LT (1) LT2888243T (es)
ME (1) ME02519B (es)
MX (1) MX360001B (es)
PL (1) PL2888243T3 (es)
PT (1) PT2888243T (es)
RS (1) RS55158B1 (es)
SG (1) SG11201408423XA (es)
SI (1) SI2888243T1 (es)
SM (1) SMT201600336B (es)
WO (1) WO2014030170A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11313246B2 (en) * 2016-11-30 2022-04-26 General Electric Company Gas turbine engine wash system
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
EP4488263A2 (en) 2022-03-02 2025-01-08 Hangzhou Bio-Sincerity Pharma-tech Co., Ltd. Phenylurea derivative and pharmaceutical use thereof
KR20250016079A (ko) 2022-03-02 2025-02-03 항저우 바이오-신세리티 파마-테크 컴퍼니 리미티드 히스타민 h3 수용체 길항제 및 이의 약학적 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798735A (zh) * 2003-06-12 2006-07-05 诺沃挪第克公司 用作激素敏感性脂肪酶的抑制剂的1-芳基-4-(芳氧基羰基)-哌嗪衍生物
US8008301B2 (en) 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
BRPI0511778A (pt) * 2004-06-02 2008-01-15 Hoffmann La Roche derivados da naftalina úteis como ligantes do receptor 3 da histamina
CN1972926B (zh) 2004-06-21 2011-02-16 霍夫曼-拉罗奇有限公司 作为组胺受体拮抗剂的吲哚衍生物
CA2577061C (en) 2004-08-23 2014-02-18 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
CN101316838B (zh) * 2005-11-30 2013-01-30 霍夫曼-拉罗奇有限公司 用作h3调节剂的1,1-二氧代-硫代吗啉基吲哚基甲酮衍生物
WO2007137955A1 (en) 2006-05-30 2007-12-06 F. Hoffmann-La Roche Ag Piperidinyl pyrimidine derivatives
US7534788B2 (en) * 2007-07-25 2009-05-19 Hoffmann-La Roche Inc. Benzofuran and benzothiophene-2-carboxylic acid amide derivatives
CL2008002622A1 (es) 2007-09-06 2009-11-27 Glaxo Group Ltd 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
US7799816B2 (en) 2008-02-04 2010-09-21 Roche Palo Alto Llc Imidazolinylmethyl aryl sulfonamide
US20110046130A1 (en) 2008-03-31 2011-02-24 Evotec Ag Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
CA2721303C (en) 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
ES2558531T3 (es) * 2010-09-02 2016-02-05 Suven Life Sciences Limited Compuestos de heterociclilo como ligandos de receptores de histamina H3

Also Published As

Publication number Publication date
BR112015001524B1 (pt) 2022-04-05
ES2592819T3 (es) 2016-12-01
AU2012388383A1 (en) 2015-01-22
BR112015001524A2 (pt) 2017-07-04
EA025136B1 (ru) 2016-11-30
JP5981654B2 (ja) 2016-08-31
PT2888243T (pt) 2016-09-21
ME02519B (me) 2017-02-20
KR20150024918A (ko) 2015-03-09
US9328092B2 (en) 2016-05-03
AU2012388383B2 (en) 2015-12-10
MX360001B (es) 2018-10-18
IL236437A (en) 2016-12-29
EA201590413A1 (ru) 2015-06-30
KR101707343B1 (ko) 2017-02-15
CY1118035T1 (el) 2017-05-17
SG11201408423XA (en) 2015-01-29
CA2878217C (en) 2016-05-17
EP2888243B1 (en) 2016-08-17
US20150218129A1 (en) 2015-08-06
CN104540812B (zh) 2016-08-24
DK2888243T3 (en) 2016-09-26
HK1204620A1 (en) 2015-11-27
HRP20161167T1 (hr) 2016-11-04
WO2014030170A1 (en) 2014-02-27
AU2012388383C1 (en) 2016-03-17
MX2015000064A (es) 2015-04-08
CA2878217A1 (en) 2014-02-27
EP2888243A1 (en) 2015-07-01
CN104540812A (zh) 2015-04-22
SI2888243T1 (sl) 2016-11-30
JP2015526462A (ja) 2015-09-10
HUE030901T2 (en) 2017-06-28
IL236437A0 (en) 2015-02-26
SMT201600336B (it) 2016-11-10
NZ703323A (en) 2016-03-31
RS55158B1 (sr) 2017-01-31
LT2888243T (lt) 2016-10-10
PL2888243T3 (pl) 2017-01-31

Similar Documents

Publication Publication Date Title
AP2014007810A0 (en) Imidazopyrrolidinone compounds
GB201209138D0 (en) Compounds
GB201215357D0 (en) Compounds
GB201214750D0 (en) Compounds
AP2015008591A0 (en) Heterocyclic compounds
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
ZA201306328B (en) Novel compounds as histamine h3 receptor ligands
GB201209096D0 (en) Compounds
IL236437A0 (en) Acrylamide compounds as ligands for the histamine h3 receptor
GB201219820D0 (en) Compounds
ZA201301143B (en) Heterocyclyl compounds as histamine h3 receptor ligands
GB201217310D0 (en) Compounds
ZA201409244B (en) Acrylamide compounds as histamine h3 receptor ligands
TH1501000921A (th) สารประกอบอะคริลาไมด์ในฐานะลิแกนด์ของฮิสตะมีน h3 รีเซปเตอร์
GB201211308D0 (en) Compounds for use
GB201211086D0 (en) Novel anti-cancer compounds
TH1401001203B (th) สารประกอบเฮเทอโรเอริลในฐานะที่เป็น 5-ht4 รีเซปเตอร์ลิแกนด์
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218758D0 (en) Compounds
GB201218776D0 (en) Compounds